---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-088168"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2025-06-20T23:59:59+00:00"
generated_at: "2026-05-19T01:40:58.616069+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Galecto stockholders approve director elections, preferred stock conversion, and auditor ratification

## Summary
- Carl Goldfischer and David Shapiro elected as Class II directors with 219,253 and 226,360 votes for; 435,515 broker non-votes.
- Preferred stock conversion approved: 226,407 for, 15,099 against, 800 abstain; 435,515 broker non-votes.
- Ratification of EY as auditor approved: 660,974 for, 16,319 against, 528 abstain; no broker non-votes.

## SEC filing metadata
- accession: 0000950170-25-088168
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2025-06-20T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000095017025088168/0000950170-25-088168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000095017025088168/glto-20250618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-088168
- JSON: https://secwatch.observer/filing/0000950170-25-088168.json
- Plain text: https://secwatch.observer/filing/0000950170-25-088168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.